About 3 Trademarks found that are owned by Synox TherapeutIcs Limited

Humanised antibody-based drugs for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, namely, humanised antibody emactuzumab targeting the CSF1R (colony stimulating factor 1 receptor) in cancer for the treatment of cancer and inflammatory diseases; pharmaceutical products, namely, inhibitors of CSF1R and macrophage function for the treatment of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, namely, inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of TGCT (tenosynovial giant cell tumour)/PVNS (pigmented villonodular synovitis); pharmaceutical compounds for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases; biological preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer and/or other oncological, autoimmune and inflammatory diseases

The mark consists of large lowercase and uppercase letters spelling "SynOx" above the word "Therapeutics" in a smaller font below and to the right hand side, inside 3 imperfect circles.

Pharmaceutical products for the prevention and treatment of cancer